Albert Einstein Cancer Center

Conjugated equine estrogen levels increase the risk of benign proliferative breast disease

This multi-institutional study led by AECC’s Tom Rohan and colleagues, showed that estrogen hormone therapy (conjugated equine estrogen) was associated with a more than two-fold increase in the risk of benign proliferative breast disease in postmenopausal women, a condition associated with increased risk of breast cancer. These data provide novel evidence for the role of estrogen in benign breast disease, which may be an early step in the development of some breast cancers. The study points to the possible targeting of estrogen as a means of lowering the risk of breast cancer in high-risk women, including women with a history of benign breast disease. 

 
Click here to log in